Popular weight-loss drugs linked to unexpected male fertility benefit

Key Points:

• Research presented at ENDO 2026 indicates that GLP-1 weight-loss medications may improve male fertility by enhancing testosterone levels, sperm quality, and metabolic health in obese men with low testosterone linked to obesity.
• The systematic review of five randomized controlled trials found that GLP-1 drugs like liraglutide and semaglutide did not suppress male reproductive hormones and showed benefits such as improved hormone levels, sperm concentration, and cholesterol profiles during weight loss.
• One study highlighted liraglutide's superior health outcomes compared to hormone replacement therapy in obese men with functional hypogonadism, while another showed semaglutide improved sperm morphology and maintained testosterone levels.
• Despite promising results, the evidence base is limited and heterogeneous, prompting researchers to call for larger, more targeted clinical trials to confirm these findings and better understand the impact of GLP-1 medications on male reproductive health.
• Experts like Dr. Anthony Puopolo express cautious optimism, emphasizing that while early data is encouraging, further research is needed to fully establish the role of GLP-1 drugs in improving fertility among obese men with low testosterone.